Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality
Top Cited Papers
- 1 March 2008
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (3), 1028-1033
- https://doi.org/10.1128/aac.01020-07
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging nosocomial pathogen. Little is known about its risk factors or mortality. We performed a case-case-control study to assess the risks for CRKP isolation and a retrospective cohort study to assess mortality in three groups of hospitalized adults: (i) patients from whom CRKP was isolated, (ii) patients from whom carbapenem-susceptible Klebsiella spp. (CSKS) were isolated, and (iii) controls from whom no Klebsiella spp. were isolated. After adjustment for length of stay (LOS), the demographics, comorbidities, and exposures of each case group were compared with those of the controls. Significant covariates were incorporated into LOS-adjusted multivariable models. In the mortality study, we evaluated the effect of CRKP on in-hospital death. There were 48 patients with CRKP isolation (21 died [44%]), 56 patients with CSKS isolation (7 died [12.5%]), and 59 controls (1 died [2%]). Independent risk factors for CRKP isolation were poor functional status (odds ratio [OR], 15.4; 95% confidence interval [CI], 4.0 to 58.6; P < 0.001); intensive care unit (ICU) stay (OR, 17.4; 95% CI, 1.5 to 201.9; P = 0.02); and receipt of antibiotics (OR, 4.4; 95% CI, 1.0 to 19.2; P = 0.05), particularly fluoroquinolones (OR, 7.2; 95% CI, 1.1 to 49.4; P = 0.04). CRKP was independently associated with death when patients with CRKP were compared with patients with CSKS (OR, 5.4; 95% CI, 1.7 to 17.1; P = 0.005) and with controls (OR, 6.7; 95% CI, 2.4 to 18.8; P < 0.001). After adjustment for the severity of illness, CRKP isolation remained predictive of death, albeit with a lower OR (for the CRKP group versus the CSKS group, OR, 3.9; 95% CI, 1.1 to 13.6; and P = 0.03; for the CRKP group versus the controls, OR, 5.0; 95% CI, 1.7 to 14.8; and P = 0.004). CRKP affects patients with poor functional status, an ICU stay, and antibiotic exposure and is an independent predictor of death.Keywords
This publication has 27 references indexed in Scilit:
- Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control studyJournal of Antimicrobial Chemotherapy, 2007
- Emergence of KPC-2 and KPC-3 in Carbapenem-Resistant Klebsiella pneumoniae Strains in an Israeli HospitalAntimicrobial Agents and Chemotherapy, 2007
- Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant Escherichia coli Clones in IsraelAntimicrobial Agents and Chemotherapy, 2006
- Carbapenem Resistance inKlebsiella pneumoniaeNot Detected by Automated Susceptibility TestingEmerging Infectious Diseases, 2006
- Carbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility TestingEmerging Infectious Diseases, 2006
- Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2006
- Influx of Extended-Spectrum -Lactamase--Producing Enterobacteriaceae into the HospitalClinical Infectious Diseases, 2006
- Extended-Spectrum β-Lactamases: a Clinical UpdateClinical Microbiology Reviews, 2005
- Risk Factors for the Acquisition of Carbapenem-Resistant Klebsiella pneumoniae among Hospitalized PatientsMicrobial Drug Resistance, 2005
- Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain ofKlebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2001